Diligence memo · auto-generated · as of July 2, 2026

Dxterity Diagnostics Inc

Dxterity Diagnostics Inc looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Dxterity Diagnostics Inc operates in Medical Devices, based in RANCHO DOMINQUEZ.

Sub-sector tags: medical-devices.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Dxterity Diagnostics Inc has raised $8.7M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.8M on 2020-08-20.

Most recent recorded round closed around 2020-08-20.

Valuation (modeled)modeled

Provath models Dxterity Diagnostics Inc at approximately $77M (range $2.2M–$583M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.84× the median modeled value of Seed Medical Devices companies in 2019–2021 (23 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 13 months.

Last raise 5.9 yr ago; this sector typically re-raises about every 16 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 3.5× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 75% of Medical Devices peers (233 compared).

Modeled value ranks above 84% of those peers.

Closest niche peers: Gradian Diagnostics Inc, Regent Surgical Health Intermediate Holdings, Inc., Caliber Imaging & Diagnostics, Inc., Sure Count Surgical, LLC, Preventric Diagnostics, LLC.

Peoplefiled

8 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.